Sterilised mosquito trial slashes dengue-spreading population

More than 80 percent of a dengue fever-spreading mosquito has been wiped out in an Australian town during a landmark trial scientists said Tuesday offered hope for combating the dangerous pest globally. Researchers from Australia’s national science body CSIRO bred millions of non-biting male Aedes aegypti mosquitoes in laboratory conditions at James Cook University (JCU) in a project funded by […]

Continue reading »

TAILORx trial finds most women with early breast cancer do not benefit from chemotherapy

New findings from the groundbreaking Trial Assigning Individualized Options for Treatment (Rx), or TAILORx trial, show no benefit from chemotherapy for 70 percent of women with the most common type of breast cancer. The study found that for women with hormone receptor (HR)-positive, HER2-negative, axillary lymph node¬-negative breast cancer, treatment with chemotherapy and hormone therapy after surgery is not more […]

Continue reading »

Positive results for phase 1 trial of ivosidenib against AML

Early phase clinical trial results presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018 of 258 patients with IDH1+ acute myeloid leukemia (AML) treated with the IDH1 inhibitor ivosidenib show an overall response rate of 41.9 percent, with median progression free survival of 8.2 months. Twenty-four percent of patients achieved a complete response. The gene IDH1 […]

Continue reading »

Experimental MERS treatments enter clinical trial

Enrollment has begun in an early-stage clinical trial testing the safety of two human monoclonal antibodies (mAbs) designed to treat people infected with Middle East respiratory syndrome coronavirus (MERS-CoV). The trial is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and is funded in part by the Biomedical Advanced Research […]

Continue reading »

Trial identifies a medulloblastoma subset that requires less aggressive therapy

The youngest patients with the brain tumor medulloblastoma are among the most challenging because their rapidly developing brains limit treatment options. Now a team of researchers led by St. Jude Children’s Research Hospital have discovered a subtype that responds to a therapy that is less likely to cause long-term cognitive problems. The report appears today in the journal Lancet Oncology […]

Continue reading »

Randomized trial finds ibuprofen not a safe alternative to antibiotics for UTIs

Ibuprofen, given instead of antibiotics to women with uncomplicated urinary tract infection, (cystitis), leads to longer duration of symptoms and more serious adverse events related to the spread of the primary infection, according to a new study in PLOS Medicine by Ingvild Vik and colleagues from the University of Oslo, Norway. More than half of all women will experience an […]

Continue reading »

Trial shows chemotherapy is helping kids live with pulmonary vein stenosis

Pulmonary vein stenosis (PVS) is a rare disease in which abnormal cells build up inside the veins responsible for carrying oxygen-rich blood from the lungs to the heart. It restricts blood flow through these vessels, eventually sealing them off entirely if left untreated. Typically affecting young children, the most severe form of PVS progresses very quickly and can cause death […]

Continue reading »

Lupus treatment generates positive results in Phase III clinical trial

New research indicates that belimumab, a monoclonal antibody therapy that targets a component of the immune system, provides considerable benefits to patients with systemic lupus erythematosus (SLE), a predominately female, chronic inflammatory disease that can affect virtually any organ. The Arthritis & Rheumatology findings are encouraging because lupus is among the leading causes of death in young women. SLE is […]

Continue reading »

First-in-human clinical trial of new targeted therapy drug reports promising responses for multiple

A phase I, first-in-human study led by The University of Texas MD Anderson Cancer Center reveals for the first time, an investigational drug that is effective and safe for patients with cancers caused by an alteration in the receptor tyrosine kinase known as RET. The drug appears to be promising as a potential therapy for RET-driven cancers, such as medullary […]

Continue reading »
1 2 3